RxDoctor Payments Data

Michael Prematta, MD

Allergy & Immunology · Havertown, PANPI 1801009444

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $131,092 of the $167,881 with a category attached, or 78.1%. 46 manufacturers reported payments, led by GSK at 41.4% of the total. Reporting peaked in 2021 at $54,312 and has fallen 50.7% since, to $26,759 in 2025. Among allergy & immunology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$167,881in general payments, 2019–2025

Across 1,308 payments — averaging $128.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$70K
  • AstraZeneca$43K
  • Sanofi$26K
  • Genentech USA, Inc.$10K
  • Boehringer Ingelheim$8K
  • Regeneron Healthcare Solutions, Inc.$2K
  • plus $9K from 40 others

What the payments were for

  • Consulting fees$7,8865%
  • Speaking & faculty fees$131,09278%
  • Travel & lodging$3,0012%
  • Food & beverage$25,59815%
  • Education$3040%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$167,881 in reported general payments places this provider in the 95th percentile of 175 allergy & immunology providers in Pennsylvania.

See all allergy & immunology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$256,219
Medicare patients
418
Services billed
11,385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FasenraBenralizumab37$214,033
Trelegy ElliptaFluticasone/Umeclidin/Vilanter221$195,236
Dupixent SyringeDupilumab34$143,698
Dupixent PenDupilumab24$90,246
XolairOmalizumab24$75,749
Fasenra PenBenralizumab11$62,216
Breo ElliptaFluticasone/Vilanterol56$29,350
Breztri AerosphereBudesonide/Glycopyr/Formoterol46$27,140
Advair HfaFluticasone Propion/Salmeterol51$19,988
SymbicortBudesonide/Formoterol Fumarate59$19,222
XhanceFluticasone Propionate17$11,909
Spiriva RespimatTiotropium Bromide17$11,902
Epinephrine52$9,960
Arnuity ElliptaFluticasone Furoate25$9,106
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate37$8,080

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFasenra, Breztri Aerosphere, Symbicort$43,216$260,395142 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$69,511$233,693302 claims
Optinose US, Inc.Xhance$872$11,90917 claims
Boehringer IngelheimSpiriva Respimat$7,759$11,90217 claims
Hikma Pharmaceuticals USAEpinephrine$114$9,96052 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$105$6,46516 claims
MerckDulera$65$6,10715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 175 allergy & immunology providers in Pennsylvania.

Other allergy & immunology in Havertown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →